Finanzen von CervoMed Inc (CRVO)CRVOCervoMed Inc

CervoMed Inc (CRVO) generates its revenue primarily from ProElite, which accounts for 100.0% of total sales, equivalent to $72.00K. Understanding this concentration is critical for investors evaluating how CRVO navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, CervoMed Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -107.62%, provide a clear picture of how effectively CRVO converts its operational activities into shareholder value.

In the context of the broader market, CRVO competes directly with industry leaders such as GAIA and AACG. With a market capitalization of $39.31M, it holds a significant position in the sector. When comparing efficiency, CRVO's gross margin of N/A stands against GAIA's 85.34% and AACG's 56.37%. Such benchmarking helps identify whether CervoMed Inc is trading at a premium or discount relative to its financial performance.

CervoMed has reported substantial financial losses, with a net income of -8,072,290 USD for Q4 2025 and -6,571,656 USD for Q2 2026. The gross margin has dropped to 0% in 2026, indicating severe operational challenges. The current ratio is at 8.57, suggesting good short-term liquidity, but the overall financial health is concerning due to consistent losses.